4.19.2023 Board Book

OMA 2023

OMA Board of Trustees Board Meeting Book

April 19 , 2023 CONTENT CONFIDENTIAL – DO NOT SHARE CONTENT OUTSIDE OMA

Board of Trustees (BOT) Meeting April 19, 2023 1:00-5:00 PM ET

Zoom Information: https://obesitymedicine-org.zoom.us/j/86288809712?pwd=Ym9MUjcrL0NXQVNHVjVxMXdpODRsUT09 Meeting ID: 862 8880 9712 Passcode: 058906 Dial-In Information: 719-359-4580; 86288809712#

Presiding Officer: Dr. Angela Fitch

Time

Topic

Lead Fitch

Action

Documents

1:00 PM

Call to Order and Opening Remarks

1:01 PM 1:03 PM 1:05 PM

Roll Call

Censani

Approval of the Agenda

Fitch Fitch

Vote

Conflict of Interest Disclosures

Discussion

4 – 9

Approval of the Consent Agenda and Supporting Documents

1:10 PM

Fitch

Vote

10 – 53

1:15 PM

Past Progress and Future Plans for Obesity Pillars AMA Delegate Seats/Membership Task Force Updates and Proposal Treat or Refer Campaign and Prior Authorization (PA) Project with PRIME Education Education/Conferences Task Force Update Integration of Metabolic and Bariatric Surgery/Interventions in OMA’s Four Core Pillars Purpose of the Conference Exhibit Hall/Protocols/Policies Bariatric Medical-Surgical (BMS) Committee Compensation Survey Review Review of Diversity, Equity, and Inclusion (DEI) Committee Survey Results Break

Bays, Cuda

Discussion

1:30 PM

Fitch, Alexander

Vote

54 – 73

2:15 PM

Fitch, Primack, Bays

Vote

74 – 153

2:45 PM

Fitch

Vote

154 – 155

3:00 PM

Break

Break

Break

3:15 PM

Alexander, Fitch

Discussion

3:45 PM

Gonsahn-Bollie, Auriemma

Discussion

156 – 163

4:05 PM

Shetye

Vote

164 – 170

Gonsahn-Bollie, Christensen

4:20 PM

Discussion

171 – 190

Endorsement of the Obesity Canada Clinical Practice Guidelines (CPGs) Adding a New BOT Member to the Finance Committee OMA’s Spring 2024 Conference Theme and Associated Concepts: “Obesity Medicine 2024: A New Path Forward” Call to Adjourn and Closing Remarks IT Infrastructure Update

4:35 PM

Fitch

Vote

191 – 207

4:45 PM

Fraker

Vote

4:50 PM

Fraker

Discussion

208 – 215

4:55 PM

Fitch, Fraker

Discussion

5:00 PM

Fitch

Product

Company

Description

Type

Relationship

Board Member

CinRX is a biotech company founded in 2015 that is focused on the drug development sector.

Angela Fitch

Pharmaceuticals

CinRX

Pharmaceutical

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide Drug Manufacturers—General

Pharmaceutical

Eli Lilly

Advisory Board

Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients. Knownwell Inc. is a healthcare delivery company Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Sidekick is a social health game. It is designed to motivate and engage people towards a healthy lifestyle. Sidekick allows people to communicate, collaborate and compete with friends and colleagues, while improving their lifestyle. Suvie builds a multi-zone cool to cook kitchen robot that makes 5 star meals with zero effort. Ms.Medicine is an innovative health care organization whose mission is to raise the standard of care of women’s health. Diet Program

Biotechnology, Medical Device, diabetes

Pharmaceuticals

Gelesis

Advisory Board

Pharmaceuticals

Knownwell Inc.

Biotechnology

Stock Ownership

Pharmaceuticals

Biotechnology, pharmaceutical

Merck

Editor

Pharmaceuticals

NovoNordisk

Biotechnology, pharmaceutical

Advisory Board

Biotechnology

Behavior App

Sidekick Health

Nutrition

Jenny Craig

Food and beverage

Science Advisory Board

Nutrition

Suvie

Food and beverage

Advisor

Turn-Key Business Solutions MsMedicine

Health Care

Advisory Board

FoundHealth.com offers information to help patients discover a range of treatments for their health challenges Health Care

Turn-Key Business Solutions Found Health

Advisory Board

This course covers critical topics in the prevention and treatment of obesity and related disorders presented by authorities from the country’s leading obesity treatment centers.

Harvard Blackburn Obesity Medicine

Education

Education

Co-Director

The American College of Physicians (ACP) is a national organization of internists, who specialize in the diagnosis, treatment, and care of adults Association

501C-6 / 501C-3 Organizations

American College of Physicians (ACP)

Member

The American Society for Metabolic and Bariatric Surgery (ASMBS) is the largest national society for this specialty. The vision of the Society is to improve public health and well being by lessening the burden of the disease of obesity and related diseases throughout the world. The Obesity Society (TOS) is the leading scientific society dedicated to the study of obesity.

501C-6 / 501C-3 Organizations 501C-6 / 501C-3 Organizations

American Society of Metabolic and Bariatric Surgery (ASMBS)

Association

Member

General Member, planning committee

The Obesity Society (TOS)

Association

Company Description

Type

Relationship

Product

Company

Board Member

Currax Pharmaceuticals LLC is a patient-first pharmaceutical company focused on the number one and number two preventable deaths in the United States: smoking addiction and obesity.

Ethan Lazarus

Pharmaceutical

Currax

Pharmaceutical

Speaker, Advisory Board

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide Drug Manufacturers—General

Advisory Board - MAY 18th and 19th 2023

Pharmaceutical

Eli Lilly

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company committed to transforming the care for patients living with rare genetic diseases of obesity.

Speakers Bureau

Pharmaceutical

NovoNordisk

Biotechnology, pharmaceutical

Consultant in development of hyperphagia assessment tool

Pharmaceutical

Rhythm Pharmaceuticals

Biotechnology, pharmaceutical

Nestlé Health Science is a leader in the field of nutritional science, committed to redefining the management of health. We offer an extensive portfolio of science-based consumer health, medical nutrition and supplement brands. This course covers critical topics in the prevention and treatment of obesity and related disorders presented by authorities from the country’s leading obesity treatment centers. The American Academy of Family Physicians (AAFP) was founded in 1947 to promote and maintain high quality standards for family medicine, an offshoot of the classical general practitioner. The Obesity Society (TOS) is the leading scientific society dedicated to the study of obesity. The American Medical Association (AMA) is an organization of American physicians, the objective of which is “to promote the science and art of medicine and the betterment of public health.” The Colorado Medical Society (CMS) is the largest group of organized physicians in Colorado. This nonprofit organization is 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Allergan plc is an American, Irish domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. Medical devices in major areas (e.g. cardiovascular, neurology, orthopedic) Minimally invasive – surgery technologies including robotics and tracking Medical equipment: therapeutic and diagnostic Health and personal Care products Medical IT and healthcare web applications Aesthetic-medical technologies Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide based therapeutics for the treatment of obesity and liver diseases. Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California Anji Pharma is a clinical-stage biotech company with operations in the U.S., Beijing, and Shanghai. AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines. Company Description Company Description

Nutrition

Food and beverage

Nestle Nutrition

Advisory Board/Speaker

Harvard Blackburn Obesity Medicine

Education

Education

Presenter

501C-6 / 501C-3 Organizations 501C-6 / 501C-3 Organizations

American Academy of Family Physicians

Association

Member

The Obesity Society (TOS)

Association

Member/Speaker

501C-6 / 501C-3 Organizations

American Medical Association (AMA)

Association

Member, Delegate for OMA

composed of physicians, residents and medical students. It was founded in 1871 to promote the art and science of medicine and to improve public health. Association

501C-6 / 501C-3 Organizations

Colorado Medical Society

Member

Product

Company

Type

Relationship

Board Member Lydia Alexander

Type

Relationship

Product

Company

Board Member

Received Grant, Consultant/Advisor

Harold Bays

Pharmaceuticals

89Bio

Biopharmaceutical

Pharmaceuticals

Allergan

Pharmaceutical

Received Grant

Pharmaceuticals

Alon Medteck/Epitomee

Devices, therapeutics

Received Grant

Pharmaceuticals

Altimmune

Biopharmaceutical

Received Grant

Received Grant, Consultant/Advisor

Pharmaceuticals

Amgen

Biopharmaceutical

Pharmaceuticals

Anji Pharma

Biotech

Received Grant

Pharmaceuticals

AstraZeneca

Biopharmaceutical

Received Grant

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Biohaven is a clinical-stage biopharmaceutical company with proven leadership in industry and academic settings. Bionime was established in April 2003 with the goal of improving the lives of people with diabetes through better self-monitoring. Bionime is focused on designing and manufacturing accurate medical testing equipment. Boehringer Ingelheim is a pharmaceutical company that develops innovative healthcare products for both human & animal needs. CinCor is a clinical-stage biopharmaceutical company targeting cardiovascular, metabolic and kidney diseases CSL Behring is a biopharmaceutical company, manufacturing plasma derived and recombinant therapeutic products Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. Evidera provides evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products Gan & Lee Pharmaceuticals is a leading pharmaceutical company in China specializing in the development, production, and commercialization of recombinant insulin analogs and injection pens,* with plans to expand globally. Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Matinas Biopharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on redefining the intracellular delivery of nucleic acids and small molecules through its lipid nanocrystal (LNC) drug delivery platform. Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. NewAmsterdam Pharma is a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Pharmaceuticals

Biopharmaceutical

Axsome

Received Grant

Pharmaceuticals

Biopharmaceutical

Received Grant

BioHaven

Pharmaceuticals

Biotechnology

Received Grant

Bionime

Biotechnology, Medical, Pharmac eutical

Pharmaceuticals

Boehringer Ingelheim

Received Grant

Pharmaceutical

CinCor

Biopharmaceutical

Received Grant

Pharmaceutical

CSL Behring

Biopharmaceutical

Received Grant

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide Drug Manufacturers—General

Pharmaceutical

Eli Lilly

Received Grant

Received Grant, Consultant/Advisor

Pharmaceutical

Esperion

Pharmaceutical

Biopharmaceutical, biotechnology

Pharmaceutical

Evidera

Received Grant

Pharmaceutical

Gan and Lee

Pharmaceutical

Received Grant

Pharmaceutical

Madrigal

Biopharmaceutical

Received Grant

Pharmaceutical

Matinas

Biopharmaceutical

Received Grant

Pharmaceutical

Merck

Biotechnology, pharmaceutical

Received Grant

Pharmaceutical

New Amsterdam

Pharmaceutical

Received Grant

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. Pharmaceutical

Pharmaceutical

Novartis

Received Grant

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Pfizer is a pharmaceuticals and biotechnology company. Regerenron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases

Pharmaceutical

NovoNordisk

Biotechnology, pharmaceutical

Received Grant

Pharmaceutical

Pfizer

Biotechnology, pharmaceutical

Received Grant

Pharmaceutical

Regerenron

Biotechnology

Received Grant

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. We are a clinical-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Selecta Biosciences is a clinical stage biotechnology company with a commitment to solving the challenges associated with autoimmunity and unwanted immunogenicity through our pioneering ImmTOR® precision immune tolerance platform. VIVUS, Inc. is a biopharmaceutical company developing therapies for obesity, sleep apnea, diabetes and sexual health. Home Access Health Corporation, which is now a subsidiary of Everly Metavante Technologies, Inc., through its subsidiary, Metavante Corporation, provided financial technology services, software and financial services regulatory advice and consulting to its customers, consisting primarily of small to large sized financial institutions. An Academic Research Organization of Brigham & Women's Hospital and An Affiliate of Harvard Medical School The Obesity Society (TOS) is the leading scientific society dedicated to the study of obesity. The ASPC, founded in 1985, represents a multidisciplinary group of healthcare practitioners and researchers who share an interest in and a passion for preventive cardiology. Endocrine Society is a global community of endocrine investigators and clinicians focused on improving patient care, advancing research, shaping effective policy, and ensuring the future of endocrinology. Practice Management Software The American College of Cardiology, a 49,000-member nonprofit medical society, enhances the lives of cardiovascular patients through continuous quality improvement, patient-centered care, payment innovation, and professionalism. The ADA's mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. The National Lipid Association is a 501(c)(3) organization formed in 2008 to serve as a patient education organization in the field of clinical lipidology.

Pharmaceutical

Sanofi

Pharmaceutical

Received Grant

Pharmaceutical

Biopharmaceutical

Received Grant

Satsuma

Pharmaceutical

Biotechnology

Received Grant

Selecta

Pharmaceutical

Vivus

Biopharmaceutical

Received Grant

Health, was founded to provide customers with health information through simple, self-collected lab tests Health Care

Laboratory Testing Legal Technology

Home Access

Received Grant Received Grant

Lexicon

Legal Technology

Technology

Metavant

Business Tools

Received Grant

501C-6 / 501C-3 Organizations 501C-6 / 501C-3 Organizations

TIMI

Education

Received Grant

General Member, Fellow, Speaker

The Obesity Society (TOS)

Association

The American Society of Preventative Cardiology (ASPC)

501C-6 / 501C-3 Organizations

Association

Board Member, Fellow, Speaker

501C-6 / 501C-3 Organizations

The Endocrine Society

Association

Member

AACE is the organization focused on endocrinology, diabetes and metabolism that is most: Recognized worldwide for its clinical leadership Association

American Association of Clinical Endocrinologists (AACE)

501C-6 / 501C-3 Organizations

Member

501C-6 / 501C-3 Organizations 501C-6 / 501C-3 Organizations

American College of Cardiology (ACC)

Association

Member, Fellow, Speaker

American Diabetes Association (ADA)

Association

Member

501C-6 / 501C-3 Organizations

The National Lipid Association

Association

Producing a joint statement

Product

Company

Type

Relationship

Board Member

Company Description

Endocrine Society is a global community of endocrine investigators and clinicians focused on improving patient care, advancing research, shaping effective policy, and ensuring the future of endocrinology.

501C-6 / 501C-3 Organization+A69s

Marisa Censani

Member

The Endocrine Society

Association

The Pediatric Endocrine Society invites members to form Special Interest Groups (SIGs). SIGs provide a venue for members to network with other colleagues sharing similar interests, to provide a forum to discuss issues concerning topics relevant to the SIGs, and work towards goals that will benefit our patients and the membership of the Pediatric Endocrine Society at large. Currax Pharmaceuticals LLC is a patient-first pharmaceutical company focused on the number one and number two preventable deaths in the United States: smoking addiction and obesity. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases VIVUS, Inc. is a biopharmaceutical company developing therapies for obesity, sleep apnea, diabetes and sexual health. Nestlé Health Science is a leader in the field of nutritional science, committed to redefining the management of health. We offer an extensive portfolio of science-based consumer health, medical nutrition and supplement brands. Illinois Obesity Society is a group of health care professionals dedicated to improving the treatment of Obesity in Illinois. Company Description

501C-6 / 501C-3 Organization+A69s

Pediatric Endocrine Society (SIG)

Member, completed a three-year term as co-chair

Association

Type

Relationship

Product

Company

Board Member

Anthony Auriemma

Pharmaceuticals

Currax

Pharmaceutical

Speakers Bureau

Pharmaceuticals

NovoNordisk

Biotechnology, pharmaceutical

Speakers Bureau

Pharmaceuticals

Phenomix

Biotechnology, pharmaceutical

Consulting

Pharmaceuticals

Vivus

Biopharmaceutical

Speaker Bureau

Nutrition

Nestle Nutrition

Food and beverage

Consulting

501C-6 / 501C-3 Organizations

Illinois Obesity Society

Association

Board of Trustee Member

Type

Product

Company

Relationship

Board Member

Company Description

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide Drug Manufacturers—General

Sandra Christensen

Pharmaceuticals

Eli Lilly

Advisory Board

Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The Obesity Society (TOS) is the leading scientific society dedicated to the study of obesity.

Biotechnology, Medical Device, diabetes

Pharmaceuticals

Gelesis

Advisory Board

Pharmaceuticals

NovoNordisk

Biotechnology, pharmaceutical

Speakers Bureau

501C-6 / 501C-3 Organization+A69s

The Obesity Society (TOS)

Association

General Member

The Washington Obesity Society is a coalition dedicated to creating a community resource for providers in the growing field of obesity medicine. Association

501C-6 / 501C-3 Organization+A69s

Washington Obesity Society

Trustee

AANP empowers all NPs to advance accessible, person-centered, equitable, high-quality health care for diverse communities through practice, education, advocacy, research and leadership.

501C-6 / 501C-3 Organization+A69s

the American Association of Nurse Practitioners (AANP).

Member, speaker

Association

Product

Company

Type

Relationship

Board Member

Company Description

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company committed to transforming the care for patients living with rare genetic diseases of obesity. The American Academy of Pediatrics (AAP) and its member pediatricians dedicate their efforts and resources to the health, safety and well-being of infants, children, adolescents and young adults.

Suzanne Cuda

Pharmaceutical

NovoNordisk

Biotechnology, pharmaceutical

Advisory Board

Pharmaceutical

Rhythm Pharmaceuticals

Biotechnology, pharmaceutical

Gold Faculty

501C-6 / 501C-3 Organization+A69s

American Academy of Pediatrics

Association

Member

The Obesity Society (TOS) is the leading scientific society dedicated to the study of obesity.

501C-6 / 501C-3 Organization+A69s

The Obesity Society (TOS)

Association

General Member

Product

Company

Type

Relationship

Board Member

Company Description

Course and consulting business to help physicians start obesity medicine practices The American Medical Association (AMA) is an organization of American physicians, the objective of which is “to promote the science and art of medicine and the betterment of public health.”

Carolynn Francavilla Brown

Education

Weight Care Consulting

Health Care

Owner

501C-6 / 501C-3 Organization+A69s

American Medical Association (AMA)

Governing Council for private practice physicians

Association

Type

Relationship

Product

Company

Board Member

Company Description

Michelle Freshwater Board Member

Product

Company

Type

Relationship

Company Description

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Product sales in obesity medicine practice

Sylvia Gonsahn-Bollie

Pharmaceuticals

NovoNordisk

Biotechnology, pharmaceutical

Consulting

Education

Shaklee Corporation

Health Care

Ambassador

Physicians.com

Medical director

Relationship

Product

Company

Type

Board Member Bharti K. Shetye

Company Description

Type

Relationship

Product

Company

Company Description

Board Member

Currax Pharmaceuticals LLC is a patient-first pharmaceutical company focused on the number one and number two preventable deaths in the United States: smoking addiction and obesity. Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Medical educational company The Obesity Society (TOS) is the leading scientific society dedicated to the study of obesity. The American Medical Association (AMA) is an organization of American physicians, the objective of which is “to promote the science and art of medicine and the betterment of public health.”

Craig Primack

Pharmaceuticals

Currax

Pharmaceutical

Speakers Bureau

Biotechnology, Medical Device, diabetes

Pharmaceuticals

Gelesis

Advisory Board

Pharmaceuticals

Phenomix

Biotechnology, pharmaceutical

Advisor

Nutrition Education Education

Nestle Nutrition

Food and beverage

Co-Medical Director

Paradigm Pri-Med

Education

Faculty

Continuing medical education (CME) Education

CME Speaker

501C-6 / 501C-3 Organization+A69s

The Obesity Society (TOS)

Association

General Member

501C-6 / 501C-3 Organization+A69s

American Medical Association (AMA)

Association

Member

Rules of Order Policy Board Approved September 2017

Rules of Order for Board Meetings Quorum: Our bylaws state that a quorum is present if the majority of the board is present.

Order of the day: Each meeting will have an agenda which will include points to discuss, old business and new business. The leader of the meeting is referred to as the “Chair.” This may be the chairman of the board, the president, or the highest-ranking officer present at the meeting. Items to discuss: All board members may submit items to discuss. These items must be submitted at least 2 weeks prior to the scheduled meeting. Items must be submitted electronically as editable Microsoft word documents. Items must include: the person (or persons, committee, etc.) introducing the item and the date of submission. Items should be marked as informational items (board updates), discussion items (not asking for action), or action items. For action items, the specific action being requested by the board should be clearly indicated. Late items: From time to time, items of critical importance may need to be introduced within 2 weeks of the board meeting. These items will be marked in the board book as “Late” and will only be discussed after a majority vote of the board to discuss the item. Motions: Introducing a main motion 1) The chair may call on the person responsible for the next order of business. Or, when no one else has the floor, a board member may address the chair by proper title. After recognition by the chair, the board member may make a motion. 2) To make a motion, state, “I move that…,” and state your motion. For example, “I move that we discuss item #4 regarding updating our travel policy…” Regarding the above items of business, the person who introduced the item of business and who’s name appears on the item of business should introduce the motion. 3) Another member may second your motion. A second simply means that the motion should be discussed. If the motion is not seconded, it is not up for discussion. It is not lost, as there has been no vote. 4) Only if there is a second, the chair states “It has been moved and seconded that…” (state the motion). “Is there any discussion?” 5) Only one main motion may be on the floor at a time. Discussing a motion 1) All speaking points should be limited to 3 minutes. This will be enforced with a timer, and an OMA staff person will be designated to monitor the timer. A different time limit (or no time limit) may also be used if requested by a majority of the quorum, either for a single item of business, or for the entire meeting. 2) The member who made the motion is entitled to speak to it first. 3) Every member may speak to the motion. Only the motion at hand should be spoken either for or against. Each member should clearly state whether they are speaking for or against the motion. 4) A person may not speak against their own motion (however, they can vote against their own motion). 5) All discussion should be directed towards the motion. Avoid using a person’s name during the debate. 6) All questions should be directed to the chair. 7) Each member may only speak to the motion twice; however, asking a question or a brief suggestion does not count as that person’s debate.

Rules of Order Policy Board Approved September 2017

8) A person may only speak a third time with the chair’s permission. 9) Only the person who introduced the motion may speak again at the end (even if this is a third time). Voting on a motion 1) Before a vote is taken, the Chair puts the question to a vote by saying “Those in favor of the motion that… (repeat the motion) … say ‘Aye.’ Those opposed say ‘No.’” 2) Wait, then say “The motion is carried,” or “The motion is lost.” 3) If a member is in doubt about the result, he or she may call for “division.” A division is a demand for a standing vote count. This may be show of hands or ballot. 4) A majority is MORE than ½ of the votes cast by persons entitled to vote (a tie does NOT carry because it is not a majority). 5) A confidential written vote may be requested by any member of the board during in-person meetings. This would not require a second. Subsidiary Motions 1. Amending a motion a. Any main motion or resolution may be amended by: adding at the end, striking out or inserting words, substitution. b. To amend a motion, during discussion, a member may say “I move to amend the motion by…” Another member must second this amendment. c. The chair asks “Is there any discussion on the amendment? [repeat amendment].” At this point, only the amendment is discussed. d. When discussion ceases, the Chair says “Those in favor of the amendment [repeat amendment] say ‘Aye.’ Those opposed say ‘Nay.’ e. At this point, the motion carries or not. The main motion (amended or not) can now be voted on, discussion can continue, or the motion may be amended again (by another motion). f. Note, even if an amendment is passed, the main motion has still not been voted on – a separate vote is required. 2. Postpone definitely / indefinitely a. When the assembly does not want to take a position on the main question at all (indefinitely) b. When the assembly wants to delay to a certain time (definitely) 3. Motion to substitute a. When the assembly wishes to substitute a new motion for the original motion. 4. Refer a. Sends a pending motion to a committee, etc. 5. Limit debate / Extend debate 6. Lay the motion on the table (tabling the motion) a. This is used to lay the pending question aside and move on with other business. This may be appropriate when there is a more urgent question at hand, scheduling issue (people invited to speak to the board), etc. Privileged Motions 1. Call for order of the day – a member can interrupt a speaker to call for sticking with the agenda. 2. Recess – used to request an intermission (does not end the meeting)

Rules of Order Policy Board Approved September 2017

3. Adjourn – used to end the meeting. 4. Fix the time to Which to Adjourn – sets the time at which the meeting will adjourn; any unfinished business is moved to the next meeting. Incidental Motions 1. Point of order – used when member feels rules are being violated. Member may interrupt a speaker to raise a point of order. 2. Appeal – used to challenge the chair’s ruling. 3. Suspend the rules – example – suspend the time limit, allow other discussions, etc. 4. Withdraw – permits the maker of the motion to withdraw it. 5. Point of information – requests to the chair to provide information relevant to business at hand. A point of information must be in the form of a question. 6. Objection to consideration of a question – suppresses business that is irrelevant or inappropriate and undesirable to be discussed. Other Main Motions 1. Take from the table – resumes consideration of a motion laid on the table earlier. 2. Reconsider – reopens a motion to debate that has already been voted upon in the same session. 3. Rescind or amend – something previously adopted Other Rules of Conduct: 1. Be prepared – Carefully review the complete board manual before the board meeting. 2. Communicate prior to the meeting – Many items can be resolved before the meeting, saving valuable time. Or, big ticket items can be identified and proper time allocated. 3. Freedom of movement – Board members are welcome to stand, sit, or use the facilities as needed. 4. Freedom of opinion – Board members are free to express their opinions, without fear of stigmatization or personal attack by other board members. 5. Respect – Board members are expected to treat each other respectfully. 6. Attention – Board members are expected to pay attention. This requires turning off cell phones and other distracting electronic devices. Board members are expected not to be texting, emailing or making personal calls (barring emergency or urgent situations) during meetings. 7. Conflict of interest – If a real or perceived conflict exists, a board member must disclose this. Depending on the conflict, if the other board members feel the conflict is not germane to the item being discussed, the member may be allowed to discuss and vote. Other options – member may be allowed to discuss but not vote. Member may be not allowed to discuss or vote. Or, member may be asked to leave the board room for the discussion. The board should determine the level of conflict and appropriate level of involvement by the conflicted member on the issue at hand.

OMA Board of Trustees (BOT) Meeting Minutes January 9th, 2023 4:00pm – 6:00pm MST Held Virtually: https://obesitymedicine org.zoom.us/j/88530631804?pwd=VWV4aFNuSnFGdlFJOFNtZWNxQitPZz09 Call to Order: The BOT meeting was called to order at 4:03 pm (MST) by Presiding Officer, Dr. Angela Fitch Roll Call: Dr. Marisa Censani Attendees: Dr. Ethan Lazarus, Dr. Lydia Alexander, Dr. Harold Bays, Dr. Anthony Auriemma, Ms. Sandra Christensen, Dr. Suzanne Cuda, Dr. Carolynn Francavilla Brown, Dr. Michelle Freshwater, Dr. Bharti Shetye, Dr. Craig Primack, Mrs. Teresa Fraker (OMA Executive Director), and Ms. Lydia Haile (OMA Operations Specialist). - At the time of roll call, Dr. Sylvia Gonsahn-Bollie was not present however she arrived within a few minutes after roll call was completed and she was present for the entire meeting. Conflict of Interest Disclosures Dr. Bays corrected his disclosures to reflect that he is on the board of directors for the American Society for Preventative Cardiology not the National Lipid Association as currently stated in the book. Furthermore, Dr. Bays shared that was contacted by the National Lipid Association for an opportunity to produce a joint statement on obesity and cardiovascular disease that he hopes to work on in collaboration with the American Society for Preventative Cardiology. Dr. Fitch updated her disclosures to reflect her involvement with Eli Lilly, Novo Nordisk, Vivus Advisory Board, Sidekick Health, and CinRX. Dr. Censani updated her disclosures to include that she is a member of The Endocrine Society and the Pediatric Endocrine Society. Dr. Censani also shared she recently completed a three-year term as the Pediatric Endocrine Society co-chair. Ms. Christensen updated her disclosures to include that she is a trustee for the Washington Obesity Society as well as a member and a speaker for the American Association of Nurse Practitioners (AANP). Dr. Gonsahn-Bollie updated her disclosures to include that she is a Shaklee ambassador and has done consulting for Novo Nordisk. She has also been recruited to be a medical director for Phsysicans.com The above disclosure additions and corrections were updated accordingly.

Approval of the Agenda

Page | 1

Motion to approve the agenda by: Dr. Censani Second: Dr. Alexander Discussion: None Vote: No Objections

Consent Agenda : Includes the minutes from the 10/12/2022 meeting and the items OMA has signed off on Approval of the Consent Agenda Motion to approve the consent agenda by: Dr. Shetye Second: Ms. Christensen Discussion: None Vote: No Objections Introduction of new OMA staff : Executive Director, Teresa Fraker, introduced Lydia Haile as OMA’s new Operations Specialist. Lydia began on 01/03/203 and will be working closely with Teresa Fraker to achieve OMA’s goals from an operational standpoint and Ms. Haile will be the

primary staff liaison to assist with all board-related activities. FY2023 Committee (Chairs and Membership) Approval

Dr. Fitch highlighted Ms. Fraker’s suggestion of establishing primary and secondary liaison designations for the board of trustee members to the committees. This would only apply for committees with more than one BOT liaison.

Motion by: Dr. Auriemma Second: Sandra Christensen

Discussion: Ms. Fraker communicated that committee correspondence would be sent out in the next 24 hours following the BOT approval. Furthermore, she expressed a desire for the committee charters to be written in a goal-focused manner and to include the committee’s top three agenda items for the year with associated timelines. Vote: No Objections FY2023 Budget Approval Ms. Fraker discussed the budget narrative listed on page 42 of the board packet. She highlighted that OMA is overall net positive and discussed the current as well as future predictions of OMA revenue. Dr. Fitch asked the board to share their thoughts regarding the current budget and if they would prefer leaving it as presented, or if some budgetary adjustments should be made in an effort to decrease expenses. - Food and beverage costs were discussed. Ultimately, the board believes in the necessity to serve a healthy and complete meal service considering our organizational stance on nutrition for our conferences, so this expense item was not altered.

Page | 2

- OMA leadership attendance at other society’s meetings (EASO, TOS, ASMBS, etc.) was discussed. The board prefers having one to two attendees/representatives at other organization’s conferences in order to increase OMA recognition in particular as this is in alignment with OMA’s strategic plan. Motion to approve the FY2023 budget as presented by: Dr. Cuda

Second: Dr. Bays Discussion: None Vote: No Objections

Executive Committee (EC) Meeting Cadence for 2023 Dr. Fitch shared that the Executive Committee (EC) will begin meeting on 4 th Thursday of each month at 5pm ET beginning in January 2023. These meetings are open for anyone on the board to attend but are not required for those board members who are not part of the EC. The minutes from the EC meetings will be shared with all members of the board. Treat and Refer Campaign Next Steps Dr. Fitch and Dr. Primack shared their vision regarding the treat and refer campaign/project noting that the next steps of the project consist of solidifying the proposal for this campaign in order to get feedback from the BOT. Following this, Dr. Primack highlighted the importance of working on a website and the messaging to our audiences (clinicians and patients alike). Grant Acquisition in order to fiscally support this campaign is expected to come from Eli Lilly, Pfizer, or Novo Nordisk, etc. Obesity Medicine (OM) Standards Development In terms of the OMA leading the development of OM Standards, the BOT discussed what OMA’s role should be. Some board members believe that we should absolutely take a leading stance while others expressed some reservations. There was discussion on the OMA providing our own definitive set of opinions to the public in order to help advise clinicians who are not necessarily OM specialists but instead are clinicians who are seeking to better navigate the field of OM. There was also discussion as to whether a set of guidelines/standards could be limiting for OM specialists whose methods of practice do not align with evidence-based OM practices. The board agrees that creation of such standards could be a unique opportunity to collaborate with other societies, but we should proceed carefully and to remain in alignment with OMA’s strategic plan.

Page | 3

OMA Items for Endorsement: ASMBS’ Guidelines for Metabolic and Bariatric Surgery/Consensus Determination The members of the board discussed ASMBS’ guidelines and the stance OMA should take in relation to these. The board expressed concerns regarding a formal endorsement to this document as the OMA did not contribute to the creation of these guidelines, in addition to the fact that certain members of the BOT do not stand by all the directives contained in these guidelines. Accepting the document as ASMBS’ standard of care and producing some sort of acknowledgment of these standards was widely agreed upon as OMA’s course of action in the event OMA were asked by ASMBS to endorse these guidelines, but there is no further action necessary at this juncture. National Board for Health and Wellness Coaching (NBHWD) Category 1 CPT Codes to the AMA The board discussed the implications of category 1 versus category 3 codes. Dr. Fitch does not think endorsement adversely affects OMA and the board expressed that as OMA’s President, Dr. Fitch should procced with the decision to endorse these codes as she prefers. Review of the Compensation Survey from the Bariatric Medical/Surgical Committee Dr. Shetye shared the great work being done by the Bariatric Medical/Surgical Committee and the diligent efforts of the committee chair, Dr. Chris Weber. Dr. Shetye shared the importance of this survey as a basis for clinicians to understand how much they should be compensated in a field as new and as rapidly growing as obesity medicine. The board shared suggestions for the survey in order to achieve its intended goal. Dr. Shetye will take the survey back to the committee for greater refinement to include both those providers practicing in medical/surgical settings as well as those providers practicing independent of medical/surgical practices. In addition, Dr. Alexander mentioned a previous compensation survey that was deployed to the OMA membership some years ago, which could also be used as a resource in making edits to the survey as it currently exists. Once the edits are finalized by the committee, Dr. Shetye will bring the survey back to the BOT for review and endorsement for deployment to OMA’s membership. General OMA Updates: Maintaining AMA Delegate Seats + Membership Categories Subcommittee - Dr. Fitch shared that this taskforce will be led by Dr. Alexander and future updates and reports will be provided to the BOT accordingly. Educational Programming Subcommittee - Dr. Fitch shared that this taskforce is geared around how we are planning our conferences and how to best meet the needs of our members at conference and she will chair this taskforce.

Page | 4

Adult and Pediatric Obesity Algorithm Releases for 2023 - The adult algorithm has been tirelessly worked on by Dr. Freshwater and Dr. Justin Tondt. Dr. Freshwater highlights the excellent efforts of Mrs. Joan Hablutzel and the OMA staff. She additionally shares that the adult algorithm will be shared with the board for a final look through to address any last major edits they may have, which will occur before the next BOT meeting. - The pediatric algorithm is making progress as well; Dr. Cuda shares that they have updated their slides and need assistance with connecting to the OMA staff as to how this publication will be translated into an eBook. Updates from ASAE’s Exceptional Board Training: Dr. Fitch and Ms. Fraker discussed the virtual board training that they attended in November 2022. As a result, Ms. Fraker hopes to develop an orientation handbook for new members of the OMA BOT. She also is considering the inclusion of a Basecamp site (or similar technology) to house board resources/policies. Dr. Fitch and Ms. Fraker also shared their interests in including professional development for board leadership and implementing board succession planning in accordance to what they learned at the training. Furthermore, they are considering the inclusion of monthly updates to OMA membership and the BOT as well as having a generative discussion regarding what’s happening in the world of obesity medicine. Dr. Censani mentioned the American Society of Association Executives (ASAE) Conference that she has previously attended as a good resource and she hopes that the OMA reconsiders including it as a general part of orientation for new board members. - Ms. Fraker alerted the group she will be sending out a monthly sign up form for various authorships in the OMA 2023 newsletter. Dr. Bays offered to be the February 2023 author. - Dr. Auriemma suggests that OMA extend free conference attendance to Past OMA Presidents in order to maintain strong and positive relationships considering their extensive service to the organization. o Dr. Francavilla Brown recommended including a badge to highlight their previous role so it is visible to attendees. Dr. Lazarus shared that the OMA policy does offer free attendance to our main conference but that it is not explicitly advertised. Dr. Lazarus suggested improving outreach efforts to these individuals by formally inviting them. Dr. Alexander agreed and shared that this could be a process we establish for a set number of years post-OMA BOT service. Dr. Censani shared that we could do some form of acknowledgment during the conference to demonstrate how we truly appreciate their efforts in supporting the OMA as well. Old and New Business: New Business

Page | 5

Old Business - Dr. Bays shared that he received an email regarding a collection of journals which are a part of OMA’s history. He was sent journals dating back to 1977. Dr. Bays plans to write a commentary in Obesity Pillars regarding these journals, by creating a “then versus now” comparison to highlight the advancements made in obesity medicine. Mrs. Fraker mentions using these journals as a conference session would be of great interest to OMA members. - Dr. Fitch mentions that according to her research, the OMA is the oldest Obesity Association in the United States and that the OMA may actually be the first Obesity Association in the world as well. Motion to adjourn the meeting by: Ms. Christensen

Second: Dr. Bays Discussion: None Vote: No Objections

Call to Adjourn and Closing Remarks: The BOT meeting was adjourned at 6:00pm (MST) by Dr. Angela Fitch

Meeting Minutes Approved by Dr. Marisa Censani on 03/15/2023

Page | 6

OMA Executive Committee (EC) Meeting Minutes January 25 th , 2023 4:00pm – 5:00pm MST Held Virtually: https://obesitymedicine org.zoom.us/j/89073362133?pwd=eHNDaGRvWDcvcDlrZTZjdFVMNENhZz09

Call to Order: The EC meeting was called to order at 4:03 pm (MST) by Dr. Angela Fitch Attendees: Dr. Angela Fitch, Dr. Ethan Lazarus, Dr. Lydia Alexander, Dr. Marisa Censani, Dr. Harold Bays, Mrs. Teresa Fraker (OMA Executive Director), and Ms. Lydia Haile (OMA Operations Specialist). OMA Marketing Plans for 2023 : E.J. Rickey was introduced as OMA’s new Director of Marketing and Business Development. He presented a marketing standpoint overview for 2023 and highlighted a website refresh, new PR positioning, and the onboarding of a new marketing automation technology. Teresa noted that she will keep the EC updated over the course of the year as these various marketing projects are implemented. Development of OM Standards: The EC discussed if there is interest in collaboration and if it makes sense for OMA’s goals. The implications of a establishing a standard of care were also considered alongside the proposal of a multiorganizational agreement/ joint statement. The EC agrees on the messaging that obesity is a disease and should be treated as such and importance of centering patient voices. Dr. Fitch reports that she will pursue opportunities for collaboration around this concept with other potential associations such as The Endocrine Society, TOS, or others. The roadblocks/roundtable group that she and Teresa have been involved with are also a good stepping off place for collaboration around the pursuit of these efforts. Dr. Fitch will report back to the group what she finds out from these continued conversations. Updates from Education (Conference Planning) and AMA Delegates/Membership Task Force Meetings were provided by Drs. Fitch and Alexander as below: - Dr. Fitch: Educational Conference Planning Task Force : Kevin Hall has accepted to speak at the April 2023 conference. Dr. Fitch will be bringing forth a proposal regarding next steps for this Task Force for consideration. - Dr. Alexander: Maintaining AMA Delegate Seats/Membership Task Force : Because the OMA values an AMA voice, we need to establish short-, medium-, and long-term goals in order to maintain our position with the AMA. The EC discussed that we must carefully plan for the June 2026 physician evaluation and are working on methods to ensure that we pass this evaluation relative to the percentage of physicians as voting members of the OMA. Dr. Alexander reports that she will bring forth a proposal likely at the April 2023 BOT Meeting once she has had the opportunity to confer with Teresa and Christian DeSousa, Director of Membership and Engagement. Disclosure of BOT Activities and Endeavors w/the OMA Membership: Ideas for how to share BOT activities with OMA Membership were discussed including potentially sharing meeting minutes or starting a quarterly update of things that the BOT/EC/Organization his working on.

Page | 1